


Abstract summaries for EULAR

Discover some of the scientific data we are presenting this year at the Annual European Congress of Rheumatology (EULAR) Virtual Congress 2021. These abstracts have been adapted into plain language summaries to help increase understanding of complex data. Please note that abstract summaries only contain information from the full scientific abstract and selected supporting references. The results of these studies may not reflect those of other studies. Summaries are not intended to provide medical advice nor intended for promotional use.



The screenshot shows a document titled "Plain Language Media Summary" with the Novartis logo. The main heading is "The effect of secukinumab on non-radiographic axial spondyloarthritis". Below the heading, it lists the full abstract title, authors (Poddubnyy D, Deodhar A), and the date (June 2021). A disclaimer states: "Please note that this summary only and selected supporting reference summary is not intended to provide medical advice." The central part of the document features a blue silhouette of a person sitting in a chair, with a list of symptoms: "spinal pain", "pain in the joints and back", "fatigue", "stiffness in the morning", and "difficulty functioning in daily life". A text block below explains that if left untreated, these symptoms can affect daily lives and limit participation in normal activities. It also states that there are approximately 3.5 million patients with axSpA (1.7 million with nr-axSpA) in the top five European countries and US, and that the prevalence of axSpA in adults is similar to that of rheumatoid arthritis.

The effect of secukinumab on non-radiographic axial spondyloarthritis at 2 years

A simplified overview of the abstract presented at EULAR June 2, 2021

[Read More \(PDF 0.3 MB\)](#)

Plain Language Media Summary

Secukinumab effect across the axial spondyloarthritis spectrum at 1 year

Full abstract title: Efficacy of Secukinumab in the Treatment of Axial Spondyloarthritis Spectrum over 1 Year in Clinical Trials

Authors: Magrey M, Walsh J, Huang J, et al.

Date: June 2021

Please note that this summary only covers the key findings of the abstract and selected supporting references. This summary is not intended to provide medical advice or to replace the role of your physician or other healthcare provider.

NOVARTIS

Design of the study

1558 patients

6 clinical trials with secukinumab

- 5 trials in AS — 1003 patients
- 1 trial in nr-axSpA — 555 patients

Secukinumab effect across the axial spondyloarthritis spectrum at 1 year

A simplified overview of the abstract presented at EULAR June 3, 2021.

[Open summary \(PDF 0.1 MB\)](#)

Plain Language Media Summary

Using sensitive ultrasound imaging to understand response of psoriatic arthritis to secukinumab over 24 weeks

Full abstract title: Responsiveness of Psoriatic Arthritis Treated with Secukinumab: A Randomized, Double-Blind, Placebo-Controlled Trial

Authors: Boers M, Conaghan PG, Scott D, et al.

Date: June 2021

Please note that this summary only covers the key findings of the abstract and selected supporting references. This summary is not intended to provide medical advice or to replace the role of your physician or other healthcare provider.

NOVARTIS

The six key "domains" of PsA:³

- Joints**
- About 80%** of PsA patients have skin symptoms prior to developing joint symptoms²
- 40-50%** of PsA patients may have dactylitis²
- 30-50%** of PsA patients may have enthesitis²
- 38%** of PsA patients may have nail psoriasis⁴
- Up to 70%** of PsA patients are impacted by axial involvement⁵

Doctors use different innovative and sensitive imaging techniques to visualize inflammation inside the body, such as magnetic resonance imaging (MRI) and Power Doppler ultrasound (PDUS) scans. PDUS can be used in PsA patients to detect early, smaller changes that may not otherwise be identified and thus can identify disease changes more sensitively.

Using sensitive ultrasound imaging to understand response of psoriatic arthritis to secukinumab over 24 weeks

A simplified overview of the abstract presented at EULAR June 4, 2021.

[Open summary \(PDF 0.2 MB\)](#)


Secukinumab seen in children

Full abstract title: Efficacy and Safety of Secukinumab in Children with Psoriatic Arthritis: Primary Results from a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial

Authors: Ruperto N, Foeldvari I, et al.

Date: June 2021

Please note that this summary or abstract and selected supporting references are for informational purposes only. This summary is not intended to provide medical advice or to replace the relationship between a patient and their healthcare provider.



Secukinumab effect in two types of arthritis seen in children and adolescents at two years

A simplified overview of the abstract presented at EULAR June 5, 2021.

[Open summary \(PDF 0.1 MB\)](#)

Source URL: <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular>

List of links present in page

- <https://prod1.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eular>
- https://prod1.novartis.com/sites/novartis_com/files/effect-of-secukinumab-on-non-radiographic-axial-spondyloarthritis-at-2-years.pdf
- https://prod1.novartis.com/sites/novartis_com/files/secukinumab-effect-across-the-axial-spondyloarthritis-spectrum-at-1-year.pdf
- https://prod1.novartis.com/sites/novartis_com/files/using-sensitive-ultrasound-imaging-to-understand-response-of-psoriatic-arthritis-to-secukinumab-over-24-weeks.pdf
- https://prod1.novartis.com/sites/novartis_com/files/secukinumab-effect-in-two-types-of-arthritis-seen-in-children-and-adolescents-at-two-years.pdf